Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Multi-Center Study to Evaluate the Safety and Efficacy of ONCT-808 in Adult Subjects With Relapsed or Refractory Aggressive B-Cell Malignancies

NCT05588440 is registered in ClinicalTrials.gov with Oncternal Therapeutics, Inc as lead sponsor.

NCT NCT05588440
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05588440 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Multi-Center Study to Evaluate the Safety and Efficacy of ONCT-808 in Adult Subjects With Relapsed or Refractory Aggressive B-Cell Malignancies
Lead sponsor
Oncternal Therapeutics, Inc
Phase
Phase 1/2
Overall status
Terminated
Start date
May 9, 2023
Completion date
September 12, 2024
Enrollment
9 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory aggressive b-cell malignancies